Skip to main content
. 2022 Apr 24;113(6):1955–1967. doi: 10.1111/cas.15355

FIGURE 6.

FIGURE 6

Flow cytometry analysis of immune cell subsets in tumor tissues. LLC tumor‐bearing mice were treated with/without riluzole (18 mg/kg) for five injections. FACS was used to analyze the components of specific immune cells in tumor tissues. (A) Neutrophil infiltration (CD45+CD11b+LY6G+) in tumors in LLC‐bearing mice treated with or without riluzole. n = 5. (B) These data were quantified as the percentage of MDSCs in CD45+ cells. (C) Flow cytometry analysis of pSTAT3 levels in neutrophils isolated from blood and tumors of LLC‐bearing mice treated with or without riluzole. n = 5. (D) Quantification of pSTAT3 percentage in neutrophils. (E) Flow cytometry CD4+ (CD45+CD4+) and CD8+ (CD45+CD8+) T cells in tumors in LLC‐bearing mice treated with or without riluzole. n = 5. (F) Quantitative analysis of the number of CD4+ and CD8+ T cells in tumors. (G) Flow cytometry regulatory T (Treg) (CD4+FOXP3+) cells in tumors in LLC‐bearing mice treated with or without riluzole. n = 5. (H) Quantitative analysis of the number of Tregs in tumors. Control, LLC‐bearing mice without riluzole treatment. *p < 0.05 between two groups; **p < 0.01 between two groups. NS, not significant